| |||||||||||||||
| Rating | Health Concerns |
|---|---|
![]() |
|
![]() |
Prostatitis (NBP, PD) |
![]() |
Thrombophlebitis |
Reliable and relatively consistent scientific data showing a substantial health benefit. Contradictory, insufficient, or preliminary
studies suggesting a health benefit or minimal health benefit. For an herb, supported by traditional use but
minimal or no scientific evidence. For a supplement, little scientific support and/or minimal
health benefit. | |
Since bromelain is not essential, deficiencies of this plant-based enzyme do not exist.
Assessing the right amount of bromelain to take is complicated. Most bromelain research was conducted years ago, when amounts used were listed in units of activity that no longer exist. These old units do not precisely convert to new ones. Today, bromelain is measured in MCUs (milk clotting units) or GDUs (gelatin dissolving units). One GDU equals approximately 1.5 MCU. Strong products contain at least 2,000 MCU (1,200–1,333 GDU) per gram (1,000 mg). A supplement containing 500 mg labelled “2,000 MCU per gram” would have 1,000 MCU of activity. Some doctors recommend as much as 3,000 MCU taken three times per day for several days, followed by 2,000 MCU three times per day.23 Much of the research uses smaller amounts, more like the equivalent of approximately 500 MCU taken four times per day. However, most of the bromelain used in the studies was enteric-coated in order to prevent it from being destroyed by gastric juice. It is likely, therefore, that currently available bromelain preparations (which typically are not enteric-coated) are of lower potency than the bromelain used in most studies.
Bromelain is generally safe and free of side effects when taken in moderate amounts. However, one preliminary report indicates increased heart rate with the use of bromelain.24 In addition, some people are allergic to bromelain. One woman reportedly developed a hives and severe swelling after taking bromelain, even though she had tolerated bromelain on two other occasions previously.25 Because bromelain acts as a blood thinner and little is known about how bromelain interacts with blood-thinning drugs, people should avoid combining such drugs with bromelain in order to reduce the theoretical risk of excessive bleeding.
Are there any drug
interactions?
Certain medicines may interact with bromelain. Refer to drug interactions for a list of those medicines.
1. Izaka K, Yamada M, Kawano T, Suyama T. Gastrointestinal absorption and anti-inflammatory effect of bromelain. Jpn J Pharmacol 1972;22:519-34.
2. Balakrishnan V, Hareendran A, Nair CS. Double-blind cross-over trial of an enzyme preparation in pancreatic steatorrhea. J Assoc Physicians India 1981;29:207-9.
3. Seligman B. Bromelain: an anti-inflammatory agent. Angiology 1962;13:508-10.
4. Cirelli MG. Treatment of inflammation and edema with bromelain. Delaware Med J 1962;34:159-67.
5. Masson M. Bromelain in the treatment of blunt injuries to the musculoskeletal system. A case observation study by an orthopedic surgeon in private practice. Fortschr Med 1995;113:303-6.
6. Ahle NW, Hamlet MP. Enzymatic frostbite eschar debridement by bromelain. Ann Emerg Med 1987;16:1063-5.
7. Hayashi M. Pharmacological studies of Shikon and Tooki. (3) Effect of topical application of the ether extracts and Shiunko on inflammatory reactions. Nippon Yakurigaku Zasshi 1977;73:205-14 [in Japanese].
8. Levensen S. Supportive therapy in burn care. Debriding agents. J Trauma 1979;19(11 Suppl):8-30.
9. Seltzer AP. Minimizing post-operative edema and ecchymoses by the use of an oral enzyme preparation (bromelain). EENT Monthly 1962;41:813-7.
10. Howat RCL, Lewis GD. The effect of bromelain therapy on episiotomy wounds—a double blind controlled clinical trial. J Obstet Gynaecol Br Commonwealth 1972;79:951-3.
11. Zatuchni GI, Colombi DJ. Bromelains therapy for the prevention of episiotomy pain. Obstet Gynecol 1967;29:275-8.
12. Taub SJ. The use of Ananase in sinusitis. A study of 60 patients. EENT Monthly 1966;45:96-8.
13. Ryan RE. A double-blind clinical evaluation of bromelains in the treatment of acute sinusitis. Headache 1967;7:13-7.
14. Mori S, Ojima Y, Hirose T, et al. The clinical effect of proteolytic enzyme containing bromelain and trypsin on urinary tract infection evaluated by double blind method. Acta Obstet GynaecolJpn 1972;19:147-53.
15. Cohen A, Goldman J. Bromelains therapy in rheumatoid arthritis. Pennsylvania Med J 1964;67:27-30.
16. Heinicke R, van der Wal L, Yokoyama M. Effect of bromelain (Ananase) on human platelet aggregation. Experientia 1972;28:844-5.
17. Nieper HA. Effect of bromelain on coronary heart disease and angina pectoris. Acta Med Empirica 1978;5:274-8.
18. Seligman B. Oral bromelains as adjuncts in the treatment of acute thrombophlebitis. Angiology 1969;20:22-6.
19. Schafer A, Adelman B. Plasma inhibition of platelet function and of arachidonic acid metabolism. J Clin Invest 1985;75:456-61.
20. Kelly GS. Bromelain: a literature review and discussion of its therapeutic applications. Altern Med Rev 1996;1:243-57 [review].
21. Desser L, Rehberger A, Paukovits W. Proteolytic enzymes and amylase induce cytokine production in peripheral blood mononuclear cells in vitro. Cancer Biother 1994;9:253-63.
22. Munzig E, Eckert K, Harrach T, et al. Bromelain protease F9 reduces the CD44 mediated adhesions of human peripheral blood lymphocytes to human umbilical vein endothelial cells. FEBS Lett 1995;351:215-8.
23. Gaby AR. The story of bromelain. Nutr Healing May 1995:3, 4, 11.
24. Gutfreund AE, Taussig SJ, Morris AK. Effect of oral bromelain on blood pressure and heart rate of hypertensive patients. Hawaii Med J 1978;37:143–6.
25. Nettis E, Napoli G, Ferrannini A, Tursi A. IgE-mediated allergy to bromelain. Allergy 2001;56:257–8.
| |||||||